Revance Therapeutics Inc. (RVNC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNC
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Revance Therapeutics Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 4, 2025.
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
RVNC STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
